AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29849032 — intervention group
Group type: COMPARATOR
Intervention: Usual care with physical activity advice (UCwA)
Number of subjects: 50
Study 26724782 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (n = 79)
Number of subjects: 133
Study 26724782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 133
Study 24913337 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 641
Study 24913337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 641
Study 24913337 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 641
Study 24913337 — intervention group
Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 641
Study 22881827 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years program supplemented by positive strategies when reading with children
Number of subjects: 112
Study 22881827 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years program
Number of subjects: 112
Study 22881827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 20520293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (20-80 mg daily)
Number of subjects: 62
Study 20520293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 20520293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (nonaugmented group)
Number of subjects: 62
Study 20520293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (augmented group)
Number of subjects: 62
Study 18282663 — intervention group
Group type: EXPERIMENTAL
Intervention: VR alcohol cue environments
Number of subjects: 40
Study 18282663 — intervention group
Group type: COMPARATOR
Intervention: VR neutral cue environments
Number of subjects: 40
Study 16192477 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (80 cGy each) plus antithymocyte globulin
Number of subjects: 37
Study 16192477 — intervention group
Group type: COMPARATOR
Intervention: Single dose of total‐body irradiation (200 cGy)
Number of subjects: 37
Study 11867842 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 102
Study 11867842 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (early group)
Number of subjects: 102
Study 10534546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin (up to 150 mg daily)
Number of subjects: 48
Study 10534546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7785952 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Sprotte needle
Number of subjects: 35
Study 7785952 — intervention group
Group type: COMPARATOR
Intervention: Conventional Quincke needle
Number of subjects: 35
Study 2127785 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Number of subjects: 166
Study 2127785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Number of subjects: 166
Study 2127785 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 166
Study 2127785 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of recombinant interferon alfa‐2b
Number of subjects: 166
Study 2127785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of recombinant interferon alfa‐2b
Number of subjects: 166
Study 493351 — intervention group
Group type: EXPERIMENTAL
Intervention: contract-relax
Number of subjects: 30
Study 493351 — intervention group
Group type: COMPARATOR
Intervention: hold-relax
Number of subjects: 30
Study 493351 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 30
Study 31103128 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Biomechanical Taping (SBMT)
Number of subjects: 0
Study 31103128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector Correcting Dysfunction Technique 1 (VCDT 1)
Number of subjects: 0
Study 31103128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector Correcting Dysfunction Technique 2 (VCDT 2)
Number of subjects: 0
Study 31103128 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Biomechanical Taping (SBMT) and Vector Correcting Dysfunction Techniques (VCDT 1 and VCDT 2)
Number of subjects: 0
Study 27680013 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg monotherapy (RM)
Number of subjects: 60
Study 27680013 — intervention group
Group type: COMPARATOR
Intervention: Standard fluence PDT (SF-PDT) plus ranibizumab
Number of subjects: 60
Study 27680013 — intervention group
Group type: COMPARATOR
Intervention: Reduced-fluence PDT (RF-PDT) plus ranibizumab
Number of subjects: 60
Study 26359900 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprexis (internet-based cognitive behavioural therapy programme)
Number of subjects: 90
Study 26359900 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study 23828828 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Therapy (MT)
Number of subjects: 611
Study 23828828 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 611
Study 23828828 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 611
Study 23828828 — intervention group
Group type: COMPARATOR
Intervention: Acute Myocardial Infarction (AMI) during follow-up
Number of subjects: 611
Study 23828828 — intervention group
Group type: COMPARATOR
Intervention: Previous AMI
Number of subjects: 611
Study 23828828 — intervention group
Group type: COMPARATOR
Intervention: AMI during follow-up
Number of subjects: 611
Study 20438039 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 35
Study 20438039 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 35
Study 19027095 — intervention group
Group type: EXPERIMENTAL
Intervention: Large randomized clinical trials
Number of subjects: 0
Study 19027095 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaanalysis
Number of subjects: 0
Study 19027095 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and aspirin therapy
Number of subjects: 0
Study 17595259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 17595259 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 14734000 — intervention group
Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio >30% with T-PSA of 3-5.99 g/ml
Number of subjects: 1385
Study 14734000 — intervention group
Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio <10% with T-PSA of 3-5.99 g/ml
Number of subjects: 1385
Study 14734000 — intervention group
Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio >30% with T-PSA of 6-9.99 g/ml
Number of subjects: 1385
Study 14734000 — intervention group
Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio <10% with T-PSA of 6-9.99 g/ml
Number of subjects: 1385
Study 11213866 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone disease management (ATDM) with telephone nurse follow-up
Number of subjects: 272
Study 11213866 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study 9810957 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP nasal spray)
Number of subjects: 22
Study 9810957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7697840 — intervention group
Group type: EXPERIMENTAL
Intervention: 92‐kD gelatinase immunostaining in unstable angina patients (n = 12)
Number of subjects: 24
Study 7697840 — intervention group
Group type: COMPARATOR
Intervention: 92‐kD gelatinase immunostaining in stable angina patients (n = 12)
Number of subjects: 24
Study 7697840 — intervention group
Group type: EXPERIMENTAL
Intervention: Active synthesis of 92‐kD gelatinase in unstable angina patients (n = 10)
Number of subjects: 24
Study 7697840 — intervention group
Group type: COMPARATOR
Intervention: Active synthesis of 92‐kD gelatinase in stable angina patients (n = 10)
Number of subjects: 24
Study 2647315 — intervention group
Group type: EXPERIMENTAL
Intervention: MQ-F-OK therapy
Number of subjects: 40
Study 2647315 — intervention group
Group type: COMPARATOR
Intervention: FAM therapy
Number of subjects: 40
Study 563620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ferrous sulfate (80 mg Fe++) and folic acid (350 microgram)
Number of subjects: 29
Study 563620 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (80 mg Fe++)
Number of subjects: 29
Study 31349916 — intervention group
Group type: EXPERIMENTAL
Intervention: 42-day course of dexamethasone (0.5 mg/kg/day × 3 days followed by a slow taper, n=30)
Number of subjects: 59
Study 31349916 — intervention group
Group type: COMPARATOR
Intervention: 9-day course of dexamethasone (0.5 mg/kg/day followed by a rapid taper, n=29)
Number of subjects: 59
Study 31349916 — intervention group
Group type: EXPERIMENTAL
Intervention: 42-day course of dexamethasone
Number of subjects: 59
Study 26472632 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation with concurrent meta-cognitive skills training (CCR + MST)
Number of subjects: 0
Study 26472632 — intervention group
Group type: COMPARATOR
Intervention: Computerized cognitive remediation alone (CCR)
Number of subjects: 0
Study 25348519 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-3781 (pleuromutilin antimicrobial agent)
Number of subjects: 129
Study 25348519 — intervention group
Group type: EXPERIMENTAL
Intervention: Population PK model (three-compartment model with first-order elimination and nonlinear protein binding)
Number of subjects: 129
Study 25348519 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analyses
Number of subjects: 129
Study 23390181 — intervention group
Group type: EXPERIMENTAL
Intervention: AD dementia prevalence in 2010
Number of subjects: 10800
Study 23390181 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected AD dementia prevalence in 2050
Number of subjects: 10800
Study 21651908 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil citrate
Number of subjects: 9
Study 21651908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19288084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg)
Number of subjects: 0
Study 19288084 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg)
Number of subjects: 0
Study 19288084 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 0
Study 19288084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16671881 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 24
Study 16671881 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 24
Study 16671881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 24
Study 16671881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 12881823 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle trainer, twice every other day, with 3 sets of 10 loaded inspirations (40%‐60% of patients' maximal inspiratory pressure [Pimax]) over a 10‐week period
Number of subjects: 15
Study 12881823 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 10390303 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 310
Study 10390303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 8758084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (3.2 mg/kg loading dose followed by 1.6 mg/kg daily)
Number of subjects: 160
Study 8758084 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine (20 mg/kg loading dose followed by 10 mg/kg every 8 h)
Number of subjects: 160
Study 8758084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 160
Study 8758084 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 160
Study 8758084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 160
Study 1881978 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsulated aspartame (400 mg)
Number of subjects: 0
Study 1881978 — intervention group
Group type: COMPARATOR
Intervention: Phenylalanine (200 mg)
Number of subjects: 0
Study 1881978 — intervention group
Group type: COMPARATOR
Intervention: Aspartic acid (200 mg)
Number of subjects: 0
Study 1881978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6578752 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 5
Study 6578752 — intervention group
Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 5
Study 3907842 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 40
Study 3907842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cianopramine
Number of subjects: 40
Study 30544716 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in savory and sweet snack intake
Number of subjects: 50
Study 30544716 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in lifestyle or body weight during the first six months
Number of subjects: 50
Study 27009752 — intervention group
Group type: EXPERIMENTAL
Intervention: Western-style diet (WD) supplemented with 2 g calcium carbonate/d for 4 weeks
Number of subjects: 0
Study 27009752 — intervention group
Group type: EXPERIMENTAL
Intervention: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) for 4 weeks
Number of subjects: 0
Study 27009752 — intervention group
Group type: COMPARATOR
Intervention: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) and 2 g calcium carbonate/d for 4 weeks
Number of subjects: 0
Study 25551175 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message appointment reminders plus thrice-weekly supportive, informational, and motivational text messages
Number of subjects: 0
Study 25551175 — intervention group
Group type: COMPARATOR
Intervention: Text message appointment reminders
Number of subjects: 0
Study 23244093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23244093 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 45
Study 23244093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 45
Study 20660224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g high‐MW oat β‐glucan/d (2,210,000 g/mol)
Number of subjects: 345
Study 20660224 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g medium‐MW oat β‐glucan/d (850,000 g/mol)
Number of subjects: 345
Study 20660224 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g medium‐MW oat β‐glucan/d (530,000 g/mol)
Number of subjects: 345
Study 20660224 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g low‐MW oat β‐glucan/d (210,000 g/mol)
Number of subjects: 345
Study 20660224 — intervention group
Group type: COMPARATOR
Intervention: Wheat fiber cereal
Number of subjects: 345
Study 18709307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling by frozen gel packs applied in the axilla for 5 min before treatment
Number of subjects: 36
Study 16132323 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 28
Study 16132323 — intervention group
Group type: COMPARATOR
Intervention: Conventional open distal gastrectomy (ODG)
Number of subjects: 28
Study 12706612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment (585 nm, 5-6 J/cm², 3 treatments at monthly intervals)
Number of subjects: 38
Study 12706612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 38
Study 10483895 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0
Study 8945144 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support group
Number of subjects: 100
Study 8945144 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 2014075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin regimen (increases at intervals of not less than 60 minutes)
Number of subjects: 123
Study 2014075 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol (oxytocin increased every 20 minutes as required)
Number of subjects: 123
Study 6804311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 200 mg daily for 28 days
Number of subjects: 18
Study 6804311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 400 mg daily for 28 days
Number of subjects: 18
Study 6804311 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g daily for 28 days
Number of subjects: 18
Study 6804311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30840040 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM HI intervention
Number of subjects: 202
Study 30840040 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study 28919386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) 400mg at the rate of 60mg/kg/min
Number of subjects: 66
Study 26910613 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral levofloxacin (500 mg)
Number of subjects: 206
Study 26910613 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 206
Study 24382030 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone with amiloride
Number of subjects: 29
Study 24382030 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 29
Study 22039165 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 100
Study 22039165 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 100
Study 22039165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22039165 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers
Number of subjects: 100
Study 19131212 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of wheat gluten hydrolysate (WGH)
Number of subjects: 30
Study 19131212 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of wheat gluten hydrolysate (WGH)
Number of subjects: 30
Study 19131212 — intervention group
Group type: COMPARATOR
Intervention: 0 g of wheat gluten hydrolysate (control)
Number of subjects: 30
Study 17682989 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg/day) for up to 6 months
Number of subjects: 20
Study 14768918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on Yintang
Number of subjects: 25
Study 14768918 — intervention group
Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture on Yintang
Number of subjects: 25
Study 28291508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg intravenous (group P, n = 30)
Number of subjects: 60
Study 28291508 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S, n = 30)
Number of subjects: 60
Study 10609905 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (28 degrees C)
Number of subjects: 45
Study 10609905 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32 degrees C)
Number of subjects: 45
Study 10609905 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (37 degrees C)
Number of subjects: 45
Study 10609905 — intervention group
Group type: EXPERIMENTAL
Intervention: C3d release
Number of subjects: 45
Study 10609905 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG fraction
Number of subjects: 45
Study 7481548 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b treatment for 1 year
Number of subjects: 42
Study 7481548 — intervention group
Group type: COMPARATOR
Intervention: Embolization of hepatic arteries
Number of subjects: 42
Study 1929253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (500 mg once daily)
Number of subjects: 94
Study 1929253 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg three times daily)
Number of subjects: 94
Study 1929253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 94
Study 6644347 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon treatment
Number of subjects: 54
Study 6644347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon treatment
Number of subjects: 54
Study 6644347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 54
Study 30115424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 274
Study 30115424 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 274
Study 27217449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg daily for 3 years
Number of subjects: 758
Study 27217449 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 years
Number of subjects: 758
Study 24206058 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 433
Study 24206058 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 433
Study 24206058 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 433
Study 22729014 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure combined with low-calorie diet
Number of subjects: 86
Study 22729014 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure combined with low-calorie diet
Number of subjects: 86
Study 19817718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 9 mg
Number of subjects: 60
Study 19817718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17513282 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal setting intervention and nutrition education intervention in addition to the basic program
Number of subjects: 2311
Study 17513282 — intervention group
Group type: COMPARATOR
Intervention: Basic program only (control group)
Number of subjects: 2311
Study 17513282 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 2311